Health Care • Biotechnology: Pharmaceutical Preparations
$3.99 ▲ +0.03
(+0.76%)
MKT CAP: $587.3M • VOL: 1.46M
52W L $2 52W H $7
ACRS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $7.8M | $18.7M | $31.2M |
| YoY Revenue Growth % | -58.2% | -40.1% | — |
| Gross Profit | $5.7M | $15.9M | — |
| Gross Margin % | 73.3% | 85.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$76.4M | -$141.9M | -$97.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$64.9M | -$132.1M | -$88.5M |
| EBITDA (Normalized) | -$76.3M | -$141.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$47.1M | -$20.1M | -$78.3M |
| Capital Expenditures (CapEx) | $111.0K | $121.0K | — |
| Free Cash Flow (FCF) | -$47.2M | -$20.2M | -$78.3M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $20.0M | $24.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $103.1M | $155.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ACRS.